VANDA PHARMACEUTICALS INC. Deferred Revenue, Additions
VANDA PHARMACEUTICALS INC. (VNDA) reported Deferred Revenue, Additions of $314.00 thousand for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-07-31.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueAdditions · last filed 2015-07-31
- VANDA PHARMACEUTICALS INC. deferred revenue, additions for the quarter ending 2015-06-30 was $75.00K.
- VANDA PHARMACEUTICALS INC. deferred revenue, additions for the quarter ending 2015-03-31 was $239.00K.
- VANDA PHARMACEUTICALS INC. deferred revenue, additions for the quarter ending 2014-12-31 was $1.00K.
- VANDA PHARMACEUTICALS INC. deferred revenue, additions for fiscal 2014 was $174.00K.
| Period end | Deferred Revenue, Additions 3 month | Deferred Revenue, Additions 6 month | Deferred Revenue, Additions 9 month | Deferred Revenue, Additions 12 month |
|---|---|---|---|---|
| 2015-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $314.00K 10-Q · filed 2015-07-31 | $315.00K derived: sum of 3 quarters · filed 2015-07-31 | |
| 2015-03-31 | $239.00K 10-Q · filed 2015-05-07 | $240.00K derived: sum of 2 quarters · filed 2015-05-07 | ||
| 2014-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $174.00K 10-K · filed 2015-03-13 | ||
| 2014-09-30 | $173.00K 10-Q · filed 2014-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |